Drug · CHEMBL405
AMPHETAMINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. AMPHETAMINE. Drugs and targets, record CHEMBL405. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL405
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Amfetamin, Amfetamine, Amphetamine resin complex, Amphetamine, dl-, Anfetamina, Dyanavel, NSC-27159, Norephedrane
- ChEMBL
- Open Targets' highest stage
- Approval, for 1 of its 9 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| SLC6A2 | Sodium-dependent noradrenaline transporter | Norepinephrine transporter releasing agent | RELEASING AGENT | https://conductscience.org/library/genes/6530 |
| SLC6A3 | Sodium-dependent dopamine transporter | Dopamine transporter releasing agent | RELEASING AGENT | https://conductscience.org/library/genes/6531 |
Source ChEMBL
Diseases9
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| attention deficit-hyperactivity disorder | Approval | ATC, DailyMed and TTD | 51 | 44 | https://conductscience.org/library/drugs?q=MONDO_0007743 |
| cocaine dependence | Phase 2/3 | ClinicalTrials.gov | 6 | 6 | https://conductscience.org/library/drugs?q=MONDO_0005186 |
| Cognitive impairment | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=HP_0100543 |
| cocaine use disorder | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=EFO_0010445 |
| major depressive disorder | Early phase 1 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0002009 |
| autism spectrum disorder | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005258 |
| depressive disorder | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0002050 |
| multiple sclerosis symptom measurement | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0803536 |
| schizophrenia | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005090 |
Source Open Targets
Trials64
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 10 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 18 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02604407 | Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD) | Phase 3 | 275 | 2017-06-14 | mixed amphetamine salts | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00889915 | Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study) | Phase 4 | 228 | 2013-09-30 | mixed amphetamine salts | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT01133847 | Interventions for Children With Attention and Reading Disorders | Phase 4 | 222 | 2017-04-11 | mixed salt amphetamine | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT01811940 | Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence | Phase 2/3 | 169 | 2018-10-12 | amphetamine | Its name | ClinicalTrials.gov |
| NCT01986075 | A Sequenced Behavioral and Medication Intervention for Cocaine Dependence | Phase 1/2 | 145 | 2022-01-25 | mixed amphetamine salts | Open Targets' reading, confirmed by the trial's result groups and NLM's indexing of its papers | ClinicalTrials.gov |
| NCT03834766 | Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD | Phase 3 | 130 | 2023-11-02 | amphetamine | Its name | ClinicalTrials.gov |
| NCT02083783 | TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | 108 | 2020-08-26 | amphetamine | Its name | ClinicalTrials.gov |
| NCT03810703 | Differential Responses to Drugs and Sweet Tastes | Phase 1 | 93 | 2023-02-22 | amphetamine | Its name | ClinicalTrials.gov |
| NCT03325881 | Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years | Phase 3 | 89 | 2019-08-13 | mixed amphetamine salts | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT02020408 | Monoamine Contributions to Neurocircuitry in Eating Disorders | Phase 4 | 88 | 2020-04-27 | amphetamine | Its name | ClinicalTrials.gov |
1 to 10 of 64
See all 64 trialsComparisons in its trials30
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Adderall-ER and Topiramate vs Placebo: Three Weeks of Cocaine Abstinence at End of Study | 9 of 64 | 0 of 63 | 127 | NCT01811940 | Trial comparisons |
| Adderall-ER and Topiramate vs Placebo: Any Three Consecutive Weeks of Abstinence During Study | 14 of 64 | 4 of 63 | 127 | NCT01811940 | Trial comparisons |
| Adderall-ER and Topiramate vs Placebo: deaths from any cause | 0 of 64 | 0 of 63 | 127 | NCT01811940 | Trial comparisons |
| Adderall-ER and Topiramate vs Placebo: serious adverse events | 2 of 64 | 2 of 63 | 127 | NCT01811940 | Trial comparisons |
| AMPH ER Tab vs Matching Placebo: deaths from any cause | 0 of 62 | 0 of 65 | 127 | NCT03834766 | Trial comparisons |
| AMPH ER Tab vs Matching Placebo: serious adverse events | 0 of 62 | 0 of 65 | 127 | NCT03834766 | Trial comparisons |
| Extended Release vs Immediate Release: serious adverse events | 0 of 62 | 0 of 62 | 124 | NCT00468143 | Trial comparisons |
| TRI102 vs Placebo: deaths from any cause | 0 of 52 | 0 of 48 | 100 | NCT02083783 | Trial comparisons |
| TRI102 vs Placebo: serious adverse events | 0 of 52 | 0 of 48 | 100 | NCT02083783 | Trial comparisons |
| Healthy Controls for 1210010989 vs Healthy Smoker Controls for 1210010989: deaths from any cause | 0 of 43 | 0 of 37 | 80 | NCT02008292 | Trial comparisons |
1 to 10 of 30
See all 30 comparisons in its trialsPapers from its trials18
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials9
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Digit Span Test | 2 | 2 | ConductCognition |
| Symbol Coding | 2 | 1 | ConductCognition |
| Continuous Performance Test | 1 | 1 | ConductCognition |
| Effort Discounting Task | 1 | 1 | ConductCognition |
| Effort for Rewards Task | 1 | 1 | ConductCognition |
| Letter-Number Sequencing Task | 1 | 1 | ConductCognition |
| Paced Visual Serial Addition Test | 1 | 1 | ConductCognition |
| Probabilistic Reward Task | 1 | 1 | ConductCognition |
| Symbol Scan Task | 1 | 1 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL405
GET https://conductscience.org/api/drugs/v1/CHEMBL405/trials?page=2